Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 11,775 shares of the Company’s ordinary shares to one non-executive employee as an equity inducement award under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on November 2, 2026 and were material to the employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).